Document is current

Article History

Received: 7 June 2024

Accepted: 12 September 2024

First Online: 1 October 2024

Declarations

:

: We acknowledge that the manuscript text and any associated images submitted for publication in the journal will be made freely accessible on the internet, available for view by the general public. We understand that the content may be reproduced on other websites or in print, may undergo translation into various languages, or may be utilized for commercial purposes.

: James W. Welsh reports the following competing interests: Accuray (SAB, consulting), Alpine Immune Science (SAB, consulting, equity), Boehringer Ingelheim (SAB, consulting), Checkmate Pharmaceuticals (SAB, consulting, equity), China Medical Tribune (SAB, consulting), Genentech (SAB, consulting), GI Innovation (SAB, consulting), Kezar Life Sciences (consulting, SAB), Legion Healthcare Partners (SAB, consulting), Life Science Dynamic Limited (SAB, consulting), McKesson Corporation (SAB, consulting), Molecular Match (equity), Nanorobotix (SAB, consulting), OligoImmune (founder), Roche (SAB, consulting), Roche Molecular Systems (SAB, consulting), Nanobiotix (Research grant, Travel expenses, SAB), BMS (Research grant), Merck (Research grant), Varian (Research grant, Travel expenses, clinical sponsored research), Reflexion (Research grant, Travel expenses, Stock options, SAB), Hotspot Therapeutics (Research grant), Gilead (Research grant), Novocure (SAB), Oncoresponse (SAB, Stock options), Astra Zeneca (consultant, Research grant), Bayer Healthcare (Research grant), Kiromic (Research grant), Alkermes (Research grant, SAB), Artidis (Research grant), Sciclone (Research grant), Takeda (Research grant), Pebble Life Science (Research grant). Sebastien Paris, Jordan Da Silva, and Célia Bienassis are employees of Nanobiotix. Hampartsoum B. Barsoumian serves as a consultant for Research Guided Cancer Treatment Consults LLC. The rest of the authors disclosed no competing interests.